The present invention relates to a method for treating severe systemic mastocytosis, more particularly for treating systemic mastocytosis in patients suffering from severe mast cell mediator release associated handicap, comprising administering a tyrosine kinase inhibitor or a pharmaceutically acceptable salt or solvate thereof, preferably masitinib or a pharmaceutically acceptable salt or solvate thereof, to patients in need thereof.